Compare Gilead Sciences, Inc. (GILD) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Northrop Grumman Corporation — how do they compare? Gilead Sciences, Inc. trades at $135 (market cap $164.99B), while Northrop Grumman Corporation trades at $574.85 (market cap $82.10B). The key difference: Gilead Sciences, Inc. is far larger — about 2× Northrop Grumman Corporation's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.47%). Which is the better fit depends on your goals.
| GILD | NOC | |
|---|---|---|
Market Cap | $164.99B | $82.10B |
Sector | Health | Industrials |
52-Week High | $155.80 | $768.02 |
52-Week Low | $110.56 | $496.02 |
Enterprise Value | $188.06B | $96.08B |
Dividend Yield | 2.47% | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Northrop Grumman (NOC) trades at $571.58, up 0.68% on the day, with a bullish technical signal driven by moving averages despite overbought RSI readings. The company reported strong Q2 2026 earnings, beating EPS estimates with $7.68 actual versus $6.82 expected, and raised full-year guidance amid a record $105 billion backlog. Fundamentals show robust profitability with a 10.48% net income margin and 26.96% ROE, while valuation metrics like a P/E of 18.17 appear reasonable relative to growth.
Outlook remains positive given defense spending tailwinds and contract wins like the $7.6 billion Sentinel program, though margin pressures and high debt levels pose risks. Analysts are bullish with a $598.57 consensus target, implying ~5% upside from current levels, supported by 20 buy ratings versus 1 sell.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
